Ultragenyx Says Metabolic Disorder Treatment Approval Likely Delayed to 2026

Dow Jones

Jul 12, 2025

By Dean Seal

Ultragenyx Pharmaceutical said federal regulators have issued a complete response letter to its application for a metabolic disorder treatment that may delay the potential approval to 2026.

The biopharmaceutical company said Friday that the Food and Drug Administration's letter requested more information and potential improvements to the UX111 treatment that would address the regulator's chemistry, manufacturing and controls-related observations from manufacturing facility inspections.

"The company believes that these observations are readily addressable, related to facilities and processes, and are not directly related to the quality of the product," Ultragenyx said.

The letter will likely delay the potential approval of UX111 to 2026, the company said. It will work with the FDA in the coming months to resolve the observations.

"We are working with urgency to respond and resubmit," Ultragenyx said.

UX111 is a gene therapy being developed for Sanfilippo syndrome type A, a rare fatal lysosomal storage disease that affects the brain and currently has no approved treatment.

Write to Dean Seal at dean.seal@wsj.com

(END) Dow Jones Newswires

July 11, 2025 16:47 ET (20:47 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2550096193"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2550096193\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2550096193?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-12 04:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2550096193","market":"sg","top_or_hot":-1,"title":"Ultragenyx Says Metabolic Disorder Treatment Approval Likely Delayed to 2026","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Dean Seal \n</p>\n<p>\n  <a href=\"https://laohu8.com/S/RARE\">Ultragenyx Pharmaceutical</a> said federal regulators have issued a complete response letter to its application for a metabolic disorder treatment that may delay the potential approval to 2026. \n</p>\n<p>\n  The biopharmaceutical company said Friday that the Food and Drug Administration's letter requested more information and potential improvements to the UX111 treatment that would address the regulator's chemistry, manufacturing and controls-related observations from manufacturing facility inspections. \n</p>\n<p>\n  \"The company believes that these observations are readily addressable, related to facilities and processes, and are not directly related to the quality of the product,\" Ultragenyx said. \n</p>\n<p>\n  The letter will likely delay the potential approval of UX111 to 2026, the company said. It will work with the FDA in the coming months to resolve the observations. \n</p>\n<p>\n  \"We are working with urgency to respond and resubmit,\" Ultragenyx said. \n</p>\n<p>\n  UX111 is a gene therapy being developed for Sanfilippo syndrome type A, a rare fatal lysosomal storage disease that affects the brain and currently has no approved treatment. \n</p>\n<p>\n  Write to Dean Seal at dean.seal@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 11, 2025 16:47 ET (20:47 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ultragenyx Says Metabolic Disorder Treatment Approval Likely Delayed to 2026</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUltragenyx Says Metabolic Disorder Treatment Approval Likely Delayed to 2026\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-07-12 04:47</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Dean Seal \n</p>\n<p>\n  <a href=\"https://laohu8.com/S/RARE\">Ultragenyx Pharmaceutical</a> said federal regulators have issued a complete response letter to its application for a metabolic disorder treatment that may delay the potential approval to 2026. \n</p>\n<p>\n  The biopharmaceutical company said Friday that the Food and Drug Administration's letter requested more information and potential improvements to the UX111 treatment that would address the regulator's chemistry, manufacturing and controls-related observations from manufacturing facility inspections. \n</p>\n<p>\n  \"The company believes that these observations are readily addressable, related to facilities and processes, and are not directly related to the quality of the product,\" Ultragenyx said. \n</p>\n<p>\n  The letter will likely delay the potential approval of UX111 to 2026, the company said. It will work with the FDA in the coming months to resolve the observations. \n</p>\n<p>\n  \"We are working with urgency to respond and resubmit,\" Ultragenyx said. \n</p>\n<p>\n  UX111 is a gene therapy being developed for Sanfilippo syndrome type A, a rare fatal lysosomal storage disease that affects the brain and currently has no approved treatment. \n</p>\n<p>\n  Write to Dean Seal at dean.seal@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 11, 2025 16:47 ET (20:47 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2550096193","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2550096193","pubTimestamp":1752266820,"columns":[{"name":"Product Release","id":31,"label_key":"productRelease"}],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Ultragenyx Pharmaceutical said federal regulators have issued a complete response letter to its application for a metabolic disorder treatment that may delay the potential approval to 2026.The biopharmaceutical company said Friday that the Food and Drug Administration's letter requested more information and potential improvements to the UX111 treatment that would address the regulator's chemistry, manufacturing and controls-related observations from manufacturing facility inspections.\"The company believes that these observations are readily addressable, related to facilities and processes, and are not directly related to the quality of the product,\" Ultragenyx said.The letter will likely delay the potential approval of UX111 to 2026, the company said. It will work with the FDA in the coming months to resolve the observations.\"We are working with urgency to respond and resubmit,\" Ultragenyx said.UX111 is a gene therapy being developed for Sanfilippo syndrome type A, a rare fatal lysosom","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","RARE":"Ultragenyx Pharmaceutical Inc"},"translate_title":"Ultragenyx表示代谢紊乱治疗批准可能推迟至2026年","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RARE":0.9},"content_text":"By Dean Seal \n\n\nUltragenyx Pharmaceutical said federal regulators have issued a complete response letter to its application for a metabolic disorder treatment that may delay the potential approval to 2026. \n\n\n  The biopharmaceutical company said Friday that the Food and Drug Administration's letter requested more information and potential improvements to the UX111 treatment that would address the regulator's chemistry, manufacturing and controls-related observations from manufacturing facility inspections. \n\n\n  \"The company believes that these observations are readily addressable, related to facilities and processes, and are not directly related to the quality of the product,\" Ultragenyx said. \n\n\n  The letter will likely delay the potential approval of UX111 to 2026, the company said. It will work with the FDA in the coming months to resolve the observations. \n\n\n  \"We are working with urgency to respond and resubmit,\" Ultragenyx said. \n\n\n  UX111 is a gene therapy being developed for Sanfilippo syndrome type A, a rare fatal lysosomal storage disease that affects the brain and currently has no approved treatment. \n\n\n  Write to Dean Seal at dean.seal@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  July 11, 2025 16:47 ET (20:47 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}